CADTH recommends the reimbursement of Descovy (emtricitabine with tenofovir alafenamide fumarate)

24 August 2016 - CADTH is in favour of the reimbursement of Gilead's new dual combination product for HIV-1 infection.

The CADTH Canadian Drug Expert Committee (CDEC) has recommended that emtricitabine/tenofovir alafenamide (FTC/TAF) be reimbursed for use in combination with other antiretrovirals (ARVs) (such as non-nucleoside reverse transcriptase inhibitors [NNRTIs] or protease inhibitors) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients aged 12 years and older (and weighing ≥ 35 kg), so long as the cost of FTC/TAF should not exceed the cost of FTC/tenofovir disoproxil fumarate (TDF).

Read CADTH's recommendation for Descovy

Michael Wonder

Posted by:

Michael Wonder